Cytokinetics, (CYTK)
The price, the headline numbers and the latest news, in one place.
Cytokinetics, (CYTK) Stock Price, Analysis & Data
| Bid | 75.69 |
| Market Cap | 10.3B |
| Revenue (ttm) | 67.7M |
| Net Income (ttm) | -894M |
| 0.36 | |
| -7.22 | |
| n/a | |
| -16.65 | |
| P/B (ttm) | -59.29 |
| P/S (ttm) | 152.25 |
| Earnings Date | Nov 5, 2026 |
| Ask | 93.33 |
| Volume | 1,400,556 |
| Avg. Volume (20D) | 2,066,249 |
| Open | 74.31 |
| Previous Close | 75.35 |
| Day's Range | 73.52 - 74.89 |
| 52-Week Range | 47.22 - 88.31 |
| Analyst | Strong<br>Buy |
| Price Target | 107.5 (45.05%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for t...
Financial Performance
In 2025, Cytokinetics,'s revenue was 88.04M, an increase of 376.56% compared to the previous year's 18.47M. Earnings were -784.96M, an increase of 33.15%.
Financial StatementsAnalyst Forecast
According to 20 analyst ratings, the average rating for CYTK stock is "Strong Buy". The 12-month stock price forecast is 107.5, which is upside of 45.05% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $28.62M misses estimates by $0, with -57.13% YoY decline.
- EPS of -1.5 exceeds estimates by 0.10, with -33.93% YoY decline.
Analysts project revenue of ... Upgrade
